arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Viatris Inc

VTRS
$18.97 ▼ -0.28 (-1.43%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
31 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Bearish
auto_awesome

Analytical Summary

Viatris Inc faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $22.1B
Dividend Yield 0.63%
Revenue Growth 4.9% ↘
Op. Margin 0.2% ↗
ROIC 0.1% ↘
FCF / Share $0.28 ↘
Trailing P/E —
Price / Book —
FCF Yield 1.5%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

31-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$3.76B
↑ +4.9% —
Net Income Profit after all expenses
$-118.80M
↓ -2482.6% —
Operating Margin Operating profit as % of sales
0.2%
↑ +107.4% 11th
FCF / Share Free cash flow per share
$0.28
↓ -6.2% —
Long-Term Debt Long-term obligations
$11.61B
↓ -6.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓
30
Financial Health ↓
35
Cash Quality ↑
13

Dividend History

Dividend / share · sourced from SEC filings
$0.48 Latest / share
+0.0% YoY
+34.3% 6-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 31 quarters